The most persistent misconception about treatment-resistant depression is that the word “resistant” means permanent. It does not. Treatment-resistant depression (TRD) is a clinical designation for major depression that has not responded adequately to at least two antidepressant medications at therapeutic doses and durations, and for the significant portion of people who meet that definition, IV ketamine therapy offers a path forward through a completely different biological mechanism than anything they have likely tried before.
What Treatment-Resistant Depression Actually Is
Treatment-resistant depression is not a character flaw, a failure of effort, or evidence that a person’s depression is uniquely severe. It is a clinical classification. When a patient with major depressive disorder, a diagnosis characterized by persistent low mood, loss of interest in daily activities, fatigue, cognitive changes, and physical symptoms lasting two or more weeks, has completed two or more antidepressant trials at adequate doses and durations without sufficient improvement, clinicians designate that pattern as treatment-resistant.
This distinction matters because it changes the clinical question. A patient who has tried one antidepressant without adequate response may simply need a different medication or a longer trial. A patient with confirmed TRD has already been through that process multiple times and needs something that reaches a different biological system entirely. Research documented by the National Institutes of Health confirms that this patient population exists, that their condition is not simply a variation on typical depression, and that treatments operating through the brain’s glutamate system rather than its serotonin pathways have demonstrated meaningful results where conventional approaches have not.
At Ketamine Wellness Infusions PA, we serve patients throughout Lower Merion Township and the greater Philadelphia area who have been through the standard options and are still struggling. That history is not a disqualifier. For many of our patients, it is the clearest indicator that IV ketamine therapy may finally be the right intervention.
Why Standard Antidepressants Fall Short for Some People
The most widely prescribed antidepressants today are selective serotonin reuptake inhibitors (SSRIs, medications that increase the availability of serotonin between neurons) and serotonin-norepinephrine reuptake inhibitors (SNRIs, which target both serotonin and norepinephrine). Research consistently supports them as effective first-line treatments for many patients with depression (National Institutes of Health). The problem is not that they fail everyone. The problem is that they fail a meaningful portion of people, and when they do, the conventional clinical response is often to try another medication from the same class, operating through the same pathway. Our overview of how ketamine differs from antidepressants for depression provides additional context on why these two approaches reach different biological targets.
That process takes time. Most antidepressants require four to six weeks to produce any therapeutic effect, if they produce one at all. A patient cycling through multiple failed trials can spend months or years in that holding pattern, experiencing side effects without benefit and gradually losing confidence that relief is possible.
There is also a biological explanation for why some people do not respond to these medications. Standard antidepressants operate almost entirely within the brain’s monoamine system, adjusting how neurotransmitters like serotonin and norepinephrine are recycled between neurons. For patients whose depression involves dysfunction in the glutamate system, specifically at the NMDA receptors (proteins on neurons that regulate synaptic activity and play a central role in how the brain forms and strengthens neural connections), serotonin-targeted medications are, in a meaningful sense, working on the wrong system. Adjusting serotonin availability cannot address a problem rooted in a different neurological pathway.
How IV Ketamine Works Differently
Ketamine does not touch the serotonin system. That distinction is the foundation of why it works for patients who have not responded to SSRIs or SNRIs.
When administered intravenously at psychiatric dosing levels, IV ketamine targets the brain’s glutamate system, binding to NMDA receptors and triggering a cascade of neurological activity. It promotes the release of brain-derived neurotrophic factor (BDNF), a protein that supports the growth and maintenance of neurons, and encourages the formation of new synaptic connections in areas of the brain where depression has caused structural changes over time. Research supports that depression reduces gray matter volume in the prefrontal cortex and hippocampus, and ketamine promotes neuroplasticity in precisely those regions.
The practical result of this mechanism is speed. Where SSRIs and SNRIs may require weeks to produce any measurable effect, IV ketamine can produce antidepressant results within hours of a single infusion for many patients, according to the National Institute of Mental Health (2024). The National Institutes of Health has documented rapid antidepressant effects in TRD patients specifically, confirming that the glutamate pathway represents a clinically distinct and effective route to relief for people the serotonin-targeted approach could not reach.
This is not a fringe treatment. Ketamine has been used safely in clinical settings for decades, originally as an anesthetic. Its application at psychiatric dosing levels for depression reflects a substantial and growing body of research, and it is now widely considered one of the most significant developments in depression treatment in a generation.
What Treatment at Our Clinic Looks Like
A standard treatment course at Ketamine Wellness Infusions PA consists of six IV infusions completed over approximately two to three weeks. Each session takes place in a calm, private room. Our founder, Jill Gabay, is a Certified Registered Nurse Anesthetist (CRNA) with more than 30 years of anesthesia experience and a member of the American Society of Ketamine Physicians, Psychotherapists and Practitioners. She is personally present for every infusion, monitoring vital signs and tending to each patient throughout the session from start to finish.
Before treatment begins, we work closely with your current provider to develop a plan suited to your specific history and diagnosis. We conduct our own psych evaluation on each patient, and we maintain coordination with your care team through and after the treatment series. You will not be handed off to unfamiliar faces or managed from a distance.
Many patients notice a meaningful shift in mood before they complete the full six sessions. Some experience improvement after the first two or three infusions. Results vary by individual, and we do not promise a specific outcome. What we do commit to is that every clinical decision we make is based on your full history and guided by your goals. Following your initial series, Jill conducts personal follow-up check-ins to assess your response and discuss next steps. For patients who experience sustained improvement, periodic maintenance infusions are often all that is needed to preserve those results over time.
For patients whose depression also carries a significant psychological or trauma-related component, we offer ketamine-assisted psychotherapy (KAP), which pairs infusion therapy with structured therapeutic support before, during, and after each session. Whether KAP is the right fit for your situation is something we discuss during your consultation.
During the infusion itself, many patients experience mild dissociation, a temporary alteration in how they perceive their surroundings and sense of time that is a normal part of ketamine’s effect at this dosing level. Most patients find the experience manageable once they understand what to expect, and many describe later sessions as deeply settling. Any discomfort resolves quickly after the infusion ends, and you are in a monitored setting with an experienced clinician for the duration. A responsible adult must drive you home following each session, and we can arrange a safe ride upon request for an additional charge if needed.
Understanding Insurance and What to Expect Financially
IV ketamine is administered off-label for depression and TRD, which means most insurance plans do not cover it. We address this directly rather than avoiding the conversation. Our team provides billing codes that you may submit to your insurance carrier for potential out-of-network reimbursement, and we encourage you to call your carrier before beginning treatment to understand what your specific plan may cover.
For patients who need financing assistance, we are happy to help guide you through available options. We collect payment at the time of treatment and accept cash and credit card. Veterans receive a 20 percent discount on treatment, and healthcare workers receive a 10 percent discount. The financial aspects of care are covered openly at your consultation because we believe that question deserves a clear answer before you commit to anything.
Frequently Asked Questions
How do I know if I have treatment-resistant depression? TRD is generally defined as major depression that has not responded adequately to at least two antidepressant medications at therapeutic doses and durations. If you have completed full trials of two or more antidepressants without sufficient improvement, you may meet the clinical definition. A consultation with our team will review your full treatment history and help determine whether IV ketamine is an appropriate next step, and we encourage you to discuss your options with your current prescribing provider as well.
How quickly does IV ketamine work for depression? Many patients report a noticeable shift in mood during or shortly after their first infusion. The full clinical picture is typically assessed after completing the six-session series. Results vary by individual, and while the speed of ketamine’s antidepressant effect is among its most consistently documented clinical qualities, we do not promise a specific timeline or outcome for any individual patient.
Can I continue taking my current antidepressants while receiving ketamine infusions? In many cases, yes. Your full medication list is reviewed at the consultation, and some medications may need to be temporarily adjusted to support the best possible response to treatment. Our care team provides clear guidance before your first infusion on what to continue, pause, or modify, and any changes to your existing medications should be made in coordination with your prescribing provider.
Does insurance cover ketamine therapy for depression? Most insurance plans do not cover IV ketamine administered off-label for depression or TRD. We provide billing codes for potential out-of-network reimbursement and recommend calling your carrier to understand your specific coverage before treatment begins. Our team walks through the financial side of treatment during your consultation so you can make a fully informed decision.
Is IV ketamine safe? Ketamine has a decades-long safety record in clinical settings. At psychiatric dosing levels for depression, administered by an experienced CRNA in a properly monitored environment, its side effect profile is well-established. Mild dissociation, temporary dizziness, and brief nausea are the most commonly reported experiences, and they resolve quickly after the session ends. Every infusion at our clinic is supervised by Jill Gabay from start to finish, with continuous vital sign monitoring throughout. You can also review our depression treatment page for a full overview of how we approach care at our Lower Merion clinic.
Key Takeaways
- Treatment-resistant depression is a clinical designation, not a prognosis. It means major depression has not responded adequately to at least two antidepressant trials at therapeutic doses and durations.
- Standard antidepressants target the serotonin system. IV ketamine targets the glutamate system through NMDA receptors, reaching a fundamentally different biological pathway.
- The National Institutes of Health and the National Institute of Mental Health have documented ketamine’s rapid antidepressant effects specifically in patients with TRD who have not responded to conventional treatments.
- A standard course at Ketamine Wellness Infusions PA consists of six infusions over two to three weeks, supervised personally by Jill Gabay, CRNA, with more than 30 years of anesthesia experience.
- Most insurance plans do not cover IV ketamine. We provide billing codes for reimbursement requests and discuss all financial options openly at the consultation.
Years of failed antidepressant trials is information, not a verdict. It tells us that the biological system those medications target may not be where your depression lives. IV ketamine reaches a different system entirely, and for many patients who arrive after years in that cycle, it is the first treatment to produce genuine relief. If you are living with treatment-resistant depression in Lower Merion Township or the greater Philadelphia area, we encourage you to explore your options and discuss your history with a qualified provider. Our team at Ketamine Wellness Infusions PA is here to give you a clear, honest assessment of whether IV ketamine is the right fit for your situation. Call us at (484) 434-8963 or schedule a consultation through our website to get started.
References
- National Institutes of Health. Antidepressant Efficacy in Treatment-Resistant Depression. https://pubmed.ncbi.nlm.nih.gov/23982301/
- National Institute of Mental Health. New Hope for Rapid-Acting Depression Treatment (2024). https://www.nimh.nih.gov/news/science-updates/2024/new-hope-for-rapid-acting-depression-treatment
- National Institutes of Health. SSRIs as First-Line Treatment for Depression and Anxiety. https://pmc.ncbi.nlm.nih.gov/articles/PMC8395812/
Medical Disclaimer
The information in this blog is for educational purposes only and does not constitute medical advice. IV ketamine therapy for depression, including treatment-resistant depression, should only be pursued under the supervision of a licensed medical provider familiar with your full medical and psychiatric history. Individual results vary. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline or go to your nearest emergency room.